Disintegrating tablets comprising licarb azepine
OwnerOskar Kalb, Marie-Christine Wolfinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical compositions comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide (also referred to as “licarbazepine”) as drug substance.
Claims20
A pharmaceutical oral controlled release composition comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide.
A pharmaceutical oral controlled release composition comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, wherein in use 70 to 90% of said 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide are released within 6 hours indicated in standard in-vitro dissolution tests at 37° in phosphate buffer having a pH of about 6.8 for a 500 mg dosage form.
A disintegrating tablet having modified release granules comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and at least one polymer as retarding agent adapted to be administered once a day.
A pharmaceutical oral controlled release composition comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide displaying a plateau profile between about 4 and 25 hours after administration.
Dependencies are inferred from the claim text.